Panuveitis

20 registered clinical trials studyying Panuveitis.

Status	Trial	Sponsor	Phase
Withdrawn	Intravitreal Sirolimus as Therapeutic Approach to Uveitis NCT01280669	Stanford University	Phase 2
Unknown	Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study NCT06085079	Massachusetts Eye Research and Surgery Institution	Phase 4
Withdrawn	Ozurdex Monotherapy Trial NCT05101928	Ottawa Hospital Research Institute	Phase 4
Terminated	Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer) NCT03656692	Mallinckrodt	Phase 4
Completed	MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301 NCT02952001	Clearside Biomedical, Inc.	—
Completed	Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis NCT03097315	Clearside Biomedical, Inc.	Phase 3
Completed	Ocular Sarcoidosis Open Label Trial of ACTHAR Gel NCT02725177	The Cleveland Clinic	N/A
Completed	Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis NCT02595398	Clearside Biomedical, Inc.	Phase 3
Completed	Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis NCT02746991	EyePoint Pharmaceuticals, Inc.	Phase 3
Completed	Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uv NCT02255032	Clearside Biomedical, Inc.	Phase 2
Completed	Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis NCT01789320	Clearside Biomedical, Inc.	Phase 1 / Phase 2
Completed	Sirolimus as Therapeutic Approach to Uveitis NCT00908466	Johns Hopkins University	Phase 1
Completed	Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis NCT00615693	Novartis	Phase 2
Completed	A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or NCT00404742	Lux Biosciences, Inc.	Phase 3
Completed	A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis NCT00404885	Lux Biosciences, Inc.	Phase 3
Completed	A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Poster NCT00404612	Lux Biosciences, Inc.	Phase 3
Unknown	Quality of Life and Visual Function in Uveitis Patients NCT00407316	The New York Eye & Ear Infirmary	—
Completed	Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB) NCT00167583	University Hospital Tuebingen	Phase 3
Completed	Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis NCT00407056	Sirion Therapeutics, Inc.	Phase 3
Completed	Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis NCT00406887	Sirion Therapeutics, Inc.	Phase 3